Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: jm2i123 who wrote (11609)	10/19/2012 11:06:28 AM
From: Mammon	1 Recommendation Read Replies (1) \| Respond to of 13111

The company still needs money to run the [putative] phase III trial. So the question is, how will they get it? Does anyone have any thoughts on this? I guess I would posit that a licensing deal or acquisition might be sooner, rather than later, at this point. I of course have no actual knowledge of such, and perhaps this is just wishful thinking on my part. I am having some trouble understanding what is taking so long on the SPA, at this point.

To: jm2i123 who wrote (11609)	10/19/2012 11:20:47 AM
From: travisnye	2 Recommendations Respond to of 13111

Hey jm2i123, I think you may need to add a money raising factor into the possible 2014 price projection. We've just seen the saw blade effect fund raising can have on a price target. I consider a Nas listing superfluous. Let the science be the megaphone. Can there be a more magnifying effect than a successful drug? (I wasn't going to post this, having canceled it until I saw Mammon's post) We will need to hear from the co. about the long SPA silence. It too is having its effect.